| scholarly article | Q13442814 |
| P2093 | author name string | Ie-Ming Shih | |
| Gad Singer | |||
| Hsueh-Wei Chang | |||
| Robert J Kurman | |||
| Sarah K R Cho | |||
| P2860 | cites work | The biology of ovarian cancer | Q74673844 |
| Somatic genetic alterations (LOH) in benign, borderline and invasive ovarian tumours: intratumoral molecular heterogeneity | Q78123234 | ||
| Digital PCR | Q24685020 | ||
| Loss of heterozygosity in tumor cells requires re-evaluation: the data are biased by the size-dependent differential sensitivity of allele detection | Q30584951 | ||
| Top-down morphogenesis of colorectal tumors | Q34481424 | ||
| Counting alleles reveals a connection between chromosome 18q loss and vascular invasion | Q39555360 | ||
| Molecular genetic analysis of appendiceal mucinous adenomas in identical twins, including one with pseudomyxoma peritonei | Q39574680 | ||
| A systematic approach to the analysis of protein phosphorylation | Q43563012 | ||
| Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors | Q45100967 | ||
| Genetic analysis of benign, low-grade, and high-grade ovarian tumors | Q46325670 | ||
| Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases. | Q53364865 | ||
| Early de novo ovarian carcinoma. A study of fourteen cases. | Q53473244 | ||
| Human epithelial ovarian cancer allelotype. | Q53480313 | ||
| Comparison of loss of heterozygosity patterns in invasive low-grade and high-grade epithelial ovarian carcinomas | Q70487479 | ||
| Ki67 antigen immunostaining (MIB 1 monoclonal antibody) in serous ovarian tumors: index of proliferative activity with prognostic significance | Q72644274 | ||
| Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy | Q72958343 | ||
| Evidence that genetic instability occurs at an early stage of colorectal tumorigenesis | Q73548893 | ||
| Micropapillary serous carcinoma of the ovary: an immunohistochemical and mutational analysis of p53 | Q74219935 | ||
| Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors | Q74608408 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1223-1228 | |
| P577 | publication date | 2002-04-01 | |
| P1433 | published in | The American Journal of Pathology | Q4744259 |
| P1476 | title | Diverse tumorigenic pathways in ovarian serous carcinoma | |
| P478 | volume | 160 |
| Q36937081 | A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib |
| Q36694967 | A novel immunohistochemical method for estimating cell cycle phase distribution in ovarian serous neoplasms: implications for the histopathological assessment of paraffin-embedded specimens |
| Q37133800 | A serum based analysis of ovarian epithelial tumorigenesis |
| Q37725019 | Agreement for tumor grade of ovarian carcinoma: analysis of archival tissues from the surveillance, epidemiology, and end results residual tissue repository |
| Q37435376 | Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas |
| Q54221402 | Association between ovarian cancer and advanced endometriosis. |
| Q34162272 | BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas |
| Q36457913 | Benign epithelial ovarian tumours-cancer precursors or markers for ovarian cancer risk? |
| Q43839796 | Borderline papillary serous tumor of the fimbriated end of the fallopian tube with peritoneal implants. |
| Q36022324 | CD40 ligand induces RIP1-dependent, necroptosis-like cell death in low-grade serous but not serous borderline ovarian tumor cells. |
| Q37756401 | Characterization and comparison of precursors of ovarian and endometrial carcinoma: parts I and II. |
| Q40534317 | Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGFbeta-RII, KRAS2, TP53 and/or CDNK2A. |
| Q79918669 | Chromosomal losses of regions on 5q and lack of high-level amplifications at 8q24 are associated with favorable prognosis for ovarian serous carcinoma |
| Q92604822 | Clinicopathological and biological analysis of PIK3CA mutation and amplification in cervical carcinomas |
| Q79825860 | Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma |
| Q38751236 | Current and emerging treatment options in the management of advanced ovarian cancer |
| Q53364711 | Cyclooxygenase-2 expression in borderline ovarian tumors. |
| Q51032882 | Cytology of human ovarian surface epithelial brushings. |
| Q38790328 | DNA Damage Response is Prominent in Ovarian High-Grade Serous Carcinomas, Especially Those with Rsf-1 (HBXAP) Overexpression |
| Q34595670 | Decreased progesterone receptor isoform expression in luteal phase fallopian tube epithelium and high-grade serous carcinoma |
| Q37276915 | Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis |
| Q51157606 | Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction. |
| Q46489948 | Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer |
| Q34189765 | Differential analysis of ovarian and endometrial cancers identifies a methylator phenotype |
| Q37219890 | Differential protein mapping of ovarian serous adenocarcinomas: identification of potential markers for distinct tumor stage. |
| Q34361640 | Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis |
| Q79366828 | Distinct subtypes of serous ovarian carcinoma identified by p53 determination |
| Q31141440 | Distinction of primary and metastatic mucinous tumors involving the ovary: analysis of size and laterality data by primary site with reevaluation of an algorithm for tumor classification |
| Q46515627 | Double-hairpin molecular-beacon-based amplification detection for gene diagnosis linked to cancer |
| Q26768502 | Dualistic classification of epithelial ovarian cancer: Is it clinically relevant? |
| Q36868408 | Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis |
| Q80839222 | Editorial. Endometrioid epithelial ovarian cancer |
| Q27003273 | Endometriosis and ovarian cancer: links, risks, and challenges faced |
| Q37335987 | Epidemiologic correlates of ovarian cortical inclusion cysts (CICs) support a dual precursor pathway to pelvic epithelial cancer |
| Q61448020 | Epigenetic therapy for ovarian cancer: promise and progress |
| Q34496401 | Estrogen biosynthesis and action in ovarian cancer |
| Q80262379 | Evaluation of normal-sized ovaries associated with primary peritoneal serous carcinoma for possible precursors of ovarian serous carcinoma |
| Q35770556 | Expression of peroxisome proliferator activated receptor gamma and cyclo-oxygenase 2 in primary and recurrent ovarian carcinoma |
| Q34216967 | Expression of serum amyloid a in human ovarian epithelial tumors: implication for a role in ovarian tumorigenesis |
| Q33511864 | Expression profiling identifies genes involved in neoplastic transformation of serous ovarian cancer |
| Q43158887 | Fallopian tube as main source for ovarian and pelvic (non-endometrial) serous carcinomas. |
| Q34604042 | Fallopian tube origin of supposed ovarian high-grade serous carcinomas |
| Q37224303 | Gene-expression profiling in epithelial ovarian cancer |
| Q50955323 | Genetic alteration and immunohistochemical staining patterns of ovarian high-grade serous adenocarcinoma with special emphasis on p53 immnnostaining pattern. |
| Q61854382 | Genetic and cytogenetic observations among different types of ovarian tumors are compatible with a progression model underlying ovarian tumorigenesis |
| Q91230214 | Genomic heterogeneity in peritoneal implants: A differential analysis of gene expression using nanostring Human Cancer Reference panel identifies a malignant signature |
| Q37933098 | Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers |
| Q39937614 | Germ cell specific protein VASA is over-expressed in epithelial ovarian cancer and disrupts DNA damage-induced G2 checkpoint |
| Q92353861 | High Frequency of PIK3CA Mutations in Low-Grade Serous Ovarian Carcinomas of Japanese Patients |
| Q51035347 | High IL-17-positive tumor immune cell infiltration is indicative for chemosensitivity of ovarian carcinoma. |
| Q55017240 | High OX40 expression in recurrent ovarian carcinoma is indicative for response to repeated chemotherapy. |
| Q51753726 | High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour. |
| Q38687061 | High-grade serous carcinoma of tubo-ovarian origin: recent developments. |
| Q36184966 | Identification of glycoproteins associated with different histological subtypes of ovarian tumors using quantitative glycoproteomics |
| Q33387074 | Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors. |
| Q35947034 | Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor. |
| Q35060446 | Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas |
| Q37815309 | Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer? |
| Q79808762 | KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants |
| Q37023905 | KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer |
| Q36939085 | KRAS/BRAF Analysis in Ovarian Low-Grade Serous Carcinoma Having Synchronous All Pathological Precursor Regions |
| Q37988903 | Key features of extrauterine pelvic serous tumours (fallopian tube, ovary, and peritoneum). |
| Q53361174 | Location of inclusion cysts in mouse ovaries in relation to age, pregnancy, and total ovulation number: implications for ovarian cancer? |
| Q64076294 | Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer |
| Q34247030 | Loss of cables, a novel gene on chromosome 18q, in ovarian cancer |
| Q47136918 | Low frequency of BRAF and KRAS mutations in Chinese patients with low-grade serous carcinoma of the ovary. |
| Q33527712 | Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary |
| Q38068618 | Low-grade and high-grade serous Mullerian carcinoma: review and analysis of publicly available gene expression profiles |
| Q38109432 | Low-grade serous carcinoma: new concepts and emerging therapies. |
| Q37301334 | Low-grade serous ovarian cancer: a unique disease |
| Q36105442 | MPO density in primary cancer biopsies of ovarian carcinoma enhances the indicative value of IL-17 for chemosensitivity |
| Q37832928 | Microarray-based gene expression studies in ovarian cancer |
| Q36805357 | Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma |
| Q53406593 | Micropapillary pattern in serous borderline ovarian tumors: does it matter? |
| Q33580777 | Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma |
| Q38067436 | Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates |
| Q38333986 | Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential |
| Q53292665 | Molecular characterization of 103 ovarian serous and mucinous tumors. |
| Q37741508 | Molecular characterization of ovarian cancer by gene-expression profiling. |
| Q34312494 | Molecular genetic analysis of ovarian serous cystadenomas |
| Q37293672 | Molecular pathogenesis of endometrial and ovarian cancer |
| Q84984261 | Molecular typing of epithelial ovarian carcinomas using inflammatory markers |
| Q37183300 | Mutational analysis of KRAS, BRAF, and TP53 genes of ovarian serous carcinomas in Korean women |
| Q36982106 | Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations |
| Q33824552 | New developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapy |
| Q50887636 | Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. |
| Q36965228 | Origin of ovarian cancer: molecular profiling |
| Q36068263 | Origins and molecular pathology of ovarian cancer |
| Q40344519 | Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer |
| Q37645709 | Ovarian cancer in endometriosis: clinical and molecular aspects |
| Q37335660 | Ovarian cancer pathogenesis: a model in evolution |
| Q37415611 | Ovarian cancer update: lessons from morphology, molecules, and mice |
| Q33807748 | Ovarian cancer: pathology, biology, and disease models |
| Q38378337 | Ovarian carcinoma diagnosis: the clinical impact of 15 years of change |
| Q38090489 | Ovarian epithelial tumors and reproductive factors: a systematic review |
| Q34998994 | Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems |
| Q26822545 | Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis |
| Q83365155 | Ovarian serous low malignant potential (borderline) tumor--does "micropapillary" matter? |
| Q35098091 | Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis |
| Q36524069 | Overexpression of S100A14 in human serous ovarian carcinoma |
| Q92944163 | PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors |
| Q37101060 | Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications |
| Q35983656 | Pathophysiological dynamics of human ovarian surface epithelial cells in epithelial ovarian carcinogenesis |
| Q80287572 | Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer |
| Q37622105 | Precursors of endometrial and ovarian carcinoma |
| Q35061331 | Prognostic relevance of acquired uniparental disomy in serous ovarian cancer |
| Q28082632 | Proteomics of ovarian cancer: functional insights and clinical applications |
| Q45817225 | Quantification of ER/PR expression in ovarian low-grade serous carcinoma |
| Q36557877 | Quaternary cytoreductive surgery in ovarian cancer: does surgical effort still matter? |
| Q27316858 | RAN nucleo-cytoplasmic transport and mitotic spindle assembly partners XPO7 and TPX2 are new prognostic biomarkers in serous epithelial ovarian cancer |
| Q83636947 | Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant |
| Q45874094 | Regulatory network involving miRNAs and genes in serous ovarian carcinoma |
| Q35189704 | Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. |
| Q35653923 | Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers. |
| Q37188853 | Role of p53 and Rb in ovarian cancer |
| Q34308729 | SNP 1772 C > T of HIF-1α gene associates with breast cancer risk in a Taiwanese population. |
| Q36768921 | Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study |
| Q36229610 | Serous and mucinous borderline (low malignant potential) tumors of the ovary |
| Q89536147 | Serous ovarian tumors: Immunohistochemical profiling as an aid to grading and understanding tumorigenesis |
| Q35085393 | Simultaneous expression of caveolin-1 and E-cadherin in ovarian carcinoma cells stabilizes adherens junctions through inhibition of src-related kinases |
| Q84582253 | Subclassification of ovarian cancer based on pathology and genetics |
| Q49518656 | Survival of Advanced Stage High-Grade Serous Ovarian Cancer Patients in the Republic of Macedonia |
| Q38270129 | The biology and clinical development of MEK inhibitors for cancer |
| Q38096241 | The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors. |
| Q36178421 | The insulin and igf-I pathway in endocrine glands carcinogenesis |
| Q35209365 | The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma |
| Q53652034 | The prognostic value of dividing epithelial ovarian cancer into type I and type II tumors based on pathologic characteristics. |
| Q84243511 | The role of p53 as a surrogate marker for chemotherapeutical responsiveness in ovarian cancer |
| Q36751103 | The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer |
| Q36963030 | The status of epidermal growth factor receptor in borderline ovarian tumours. |
| Q36866311 | Time to diagnosis of Type I or II invasive epithelial ovarian cancers: a multicentre observational study using patient questionnaire and primary care records. |
| Q35666387 | Tubal origin of ovarian endometriosis and clear cell and endometrioid carcinoma. |
| Q36767181 | Tumor markers in ovarian carcinoma |
| Q80152213 | [Molecular pathology of epithelial ovarian neoplasias: from the phenotype-genotype correlation to new targets in diagnostics and therapy] |
| Q53305324 | [Serous genital carcinoma: molecular pathogenesis and the role of tubal fimbria]. |
Search more.